Bluebird bio is working with Artemis Biosystems to evaluate its filtration technologies as part of its ongoing viral vector process development efforts.
Viral vector and vaccine production from adherent mammalian cells is typically performed using cell factories in a Scale Out fashion, i.e. by adding additional cell factory units to meet viral vector demand is cost prohibitive when running at commercial scale (eg. >200L).
Alternatively, the use of suspension cells to produce viral vectors offers a Scale Up solution which is gaining traction in the industry. Suspension cells are grown to high densities in perfusion bioreactors which allow orders of magnitude greater viral titers and the continuous removal of toxic compounds. Acoustic-based perfusion devices such as BioSep® are limited to R&D production scales. In addition, the current ATF perfusion systems cannot be used for production of viral vectors because they do not allow the viral vectors (eg. Lentiviral (LV) or Adeno Associated Virus (AAV) to permeate through the hollow fiber membrane (see caption "Competitor ATF system" in the figure below entitled "% Lentiviral Recovery at Harvest").
Artemis Biosystems has developed a scalable production system based on VHU™ perfusion technology (Patent Pending) to produce clinical or commercial quantities of viral vectors from mammalian cells in suspension culture such as HEK293 or HeLa in either a transfection or stable producer cell line mode. VHU™ Perfusion increases viral vector production by at least 1-2 orders of magnitude (ISBiotech, March 5-7, 2018). This translates in 100% viral permeation efficiency compared to zero for the control ATF which uses hollow fibers (see Figure below). Artemis Biosystems supports all gene therapy and vaccine-related needs from pilot to commercial scale by offering VHU™ Perfusion technology which provides:
"Biosep®" is a registered trademark of Applikon Biotechnology
Artemis Biosystems is the first company to offer disposable Virus Harvest Units (VHU™) specifically designed for connecting via sterile connectors with either HyPerforma™ or Xcellerex™ Single Use Bioreactors ranging in size from 50L to 2000L to produce viral vectors from suspension cell lines. VHU™ revolutionizes processing time and viral permeation efficiency to support all gene therapy and vaccine-related needs from pilot to commercial scale: • 100% efficiency harvesting virus from bioreactors • Fast processing times for quick media changes • Integration of media exchange and viral harvest in a single step • Closed, disposable Virus Harvest Units derisk production runs • Scalable for use with bioreactors ranging from 2L (VHU2™) to 1000L (VHU1000™) in perfusion mode • Customizable upon request
SPECIFICATIONS AND PERFORMANCE
"XCellerex®" is a registered trademark of General Electric Corporation.
"HyPerforma™" is a registered trademark of ThermoFisher.
Please get in touch by sending us an email at email@example.com, or call us at 617-674-2747 to discuss how VHU™ can solve your viral vector production scale up problems from pilot to commercial scale